Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers

2014 ◽  
Vol 66 (9) ◽  
pp. 1222-1230 ◽  
Author(s):  
Natália Valadares de Moraes ◽  
Gabriela Rocha Lauretti ◽  
Vera Lucia Lanchote
Keyword(s):  
Type 2 Diabetes ◽  
Neuropathic Pain ◽  
Cytochrome P450 ◽  
Extensive Metabolizers ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

scholarly journals Standard analgesics reverse burrowing deficits in a rat CCI model of neuropathic pain, but not in models of type 1 and type 2 diabetes-induced neuropathic pain

2018 ◽  
Vol 350 ◽  
pp. 129-138 ◽  
Author(s):  
Kris Rutten ◽  
Stacey A. Gould ◽  
Luke Bryden ◽  
Henri Doods ◽  
Thomas Christoph ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Neuropathic Pain ◽  
Cci Model

scholarly journals Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings

2010 ◽  
Vol 16 (5) ◽  
pp. 890-901 ◽  
Author(s):  
MARIANA CHERNER ◽  
CHAD BOUSMAN ◽  
IAN EVERALL ◽  
DANIEL BARRON ◽  
SCOTT LETENDRE ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Drug Exposure ◽  
Neuropsychological Performance ◽  
Metabolic Clearance ◽  
Extensive Metabolizers ◽  
Cytochrome P450 2D6 ◽  
Hepatitis C Infection ◽  
Similar Drug ◽  
Other Substances ◽  
P450 2D6

AbstractWhile neuropsychological deficits are evident among methamphetamine (meth) addicts, they are often unrelated to meth exposure parameters such as lifetime consumption and length of abstinence. The notion that some meth users develop neuropsychological impairments while others with similar drug exposure do not, suggests that there may be individual differences in vulnerability to the neurotoxic effects of meth. One source of differential vulnerability could come from genotypic variability in metabolic clearance of meth, dependent on the activity of cytochrome P450-2D6 (CYP2D6). We compared neuropsychological performance in 52 individuals with a history of meth dependence according with their CYP2D6 phenotype. All were free of HIV or hepatitis C infection and did not meet dependence criteria for other substances. Extensive metabolizers showed worse overall neuropsychological performance and were three times as likely to be cognitively impaired as intermediate/poor metabolizers. Groups did not differ in their demographic or meth use characteristics, nor did they evidence differences in mood disorder or other substance use. This preliminary study is the first to suggest that efficient meth metabolism is associated with worse neurocognitive outcomes in humans, and implicates the products of oxidative metabolism of meth as a possible source of brain injury. (JINS, 2010, 16, 890–901.)

scholarly journals Ankle-brachial index and diabetic neuropathy: study of 225 patients

2017 ◽  
Vol 75 (8) ◽  
pp. 533-538 ◽  
Author(s):  
Liliana Chevtchouk ◽  
Marcio Heitor Stelmo da Silva ◽  
Osvaldo José Moreira do Nascimento
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Neuropathic Pain ◽  
Disease Onset ◽  
Ankle Brachial Index ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Diabetes Patients

ABSTRACT Objective To evaluate neuropathic pain and peripheral vascular disease in diabetics and compare this with the length of time since diagnosis in type 1, and type 2 diabetes. Methods A cross-sectional study with 225 diabetics chosen from their responses on the DN4 questionnaire, who were then evaluated with the ankle-brachial index (ABI), separating type 1 diabetes from type 2 diabetes. Results A higher incidence of neuropathic pain in those over 60 years of age showed an ABI > 1.3. Neuropathic pain was related to an abnormal ABI in 144 patients (64.2%). A statistically significant value was obtained in type 2 diabetes patients with more than 10 years from disease onset, 69 with altered ABI and 25 with normal ABI. There was an altered ABI (< 0.9) observed in 33% of type 1 diabetes patients and in 67% of type 2 diabetes patients. Conclusion The ABI test in type 1 diabetes and type 2 diabetes patients is important even in those who are asymptomatic. A diagnosis of more than 10 years prior, regardless of the presence of neuropathic pain or ischemic signs, altered the ABI.

scholarly journals Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers

2000 ◽  
Vol 49 (S1) ◽  
pp. 43-47 ◽  
Author(s):  
K. D. Wilner ◽  
S. B. Demattos ◽  
R. J. Anziano ◽  
G. Apseloff ◽  
N. Gerber ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Extensive Metabolizers ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes

2012 ◽  
Vol 102 (2) ◽  
pp. 335-343 ◽  
Author(s):  
Gema Vera ◽  
Visitación López-Miranda ◽  
Esperanza Herradón ◽  
María Isabel Martín ◽  
Raquel Abalo
Keyword(s):  
Type 2 Diabetes ◽  
Neuropathic Pain ◽  
Rat Models

Type 2 Diabetes Overtakes Type 1 in Hispanic Girls

2008 ◽  
Vol 38 (15) ◽  
pp. 18
Author(s):  
SHERRY BOSCHERT
Keyword(s):  
Type 2 Diabetes
Sign in / Sign up

Export Citation Format

Share Document